Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$0.39 -0.1%	$0.39	$0.22 ▼ $1.30	$8.60M	1	3.98 million shs	665,758 shs
ADXS Ayala Pharmaceuticals	$0.05	$0.07	$0.02 ▼ $0.78	$2.29M	1.17	4,771 shs	2 shs
KZIA Novogen	$8.03 -2.9%	$8.43	$2.86 ▼ $39.05	$8.09M	2.64	72,641 shs	10,312 shs
TLPH Talphera	$0.43 -1.0%	$0.45	$0.38 ▼ $1.19	$8.72M	-0.09	147,971 shs	212,626 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	+3.71%	-12.44%	-40.10%	-59.18%
ADXS Ayala Pharmaceuticals	0.00%	+30.73%	+60.96%	+56.73%	+168.00%
KZIA Novogen	0.00%	-1.11%	-21.81%	+123.68%	-55.06%
TLPH Talphera	0.00%	+3.86%	-1.09%	-15.62%	-50.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADIL Adial Pharmaceuticals	2.243 of 5 stars	3.8	2.0	0.0	0.0	2.6	0.0	0.6
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	3.9762 of 5 stars	3.8	5.0	0.0	0.0	3.0	0.0	0.0
TLPH Talphera	3.2083 of 5 stars	3.8	5.0	0.0	0.0	3.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	3.50	Strong Buy	$8.00	1,930.46% Upside
ADXS Ayala Pharmaceuticals	0.00	N/A	N/A	N/A
KZIA Novogen	3.50	Strong Buy	$14.00	74.35% Upside
TLPH Talphera	3.50	Strong Buy	$5.00	1,075.64% Upside

Current Analyst Ratings Breakdown

Latest ADXS, TLPH, KZIA, and ADIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/10/2025	KZIA Novogen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$13.00
6/11/2025	KZIA Novogen	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$0.26 per share	N/A
ADXS Ayala Pharmaceuticals	$3.24M	0.71	N/A	N/A	($2.06) per share	-0.03
KZIA Novogen	$1.51M	5.37	N/A	N/A	($9.87) per share	-0.81
TLPH Talphera	$650K	13.41	N/A	N/A	$0.47 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$13.20M	-$1.05	N/A	N/A	N/A	N/A	-191.31%	-153.59%	N/A
ADXS Ayala Pharmaceuticals	-$48.07M	-$7.98	N/A	∞	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	-$17.56M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	-$13M	-$0.45	N/A	N/A	N/A	N/A	-146.87%	-62.93%	N/A

Latest ADXS, TLPH, KZIA, and ADIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	TLPH Talphera	-$0.1150	-$0.10	+$0.0150	-$0.10	N/A	N/A
8/13/2025	Q2 2025	ADIL Adial Pharmaceuticals	-$0.22	-$0.18	+$0.04	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.02	1.99
ADXS Ayala Pharmaceuticals	N/A	N/A	N/A
KZIA Novogen	N/A	0.21	N/A
TLPH Talphera	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
ADXS Ayala Pharmaceuticals	7.18%
KZIA Novogen	30.89%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	4.26%
ADXS Ayala Pharmaceuticals	0.63%
KZIA Novogen	1.00%
TLPH Talphera	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	21.83 million	20.90 million	No Data
ADXS Ayala Pharmaceuticals	20	42.63 million	42.36 million	Not Optionable
KZIA Novogen	12	1.01 million	997,000	Optionable
TLPH Talphera	19	20.50 million	19.85 million	Optionable

ADXS, TLPH, KZIA, and ADIL Headlines

Recent News About These Companies

Talphera, Inc. (NASDAQ:TLPH) Q2 2025 Earnings Call Transcript

August 16 at 8:54 AM | insidermonkey.com

Talphera, Inc. (NASDAQ:TLPH) Sees Significant Decrease in Short Interest

August 16 at 3:07 AM | americanbankingnews.com

Talphera, Inc.: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

August 15 at 6:35 AM | finanznachrichten.de

Talphera Cuts Expenses 14 Percent

August 15 at 2:34 AM | aol.comA

Talphera Reports Q2 2025 Financial Results and Study Progress

August 14 at 12:15 AM | tipranks.com

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

August 14 at 10:00 PM | seekingalpha.com

Talphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19M

August 14 at 8:03 PM | msn.com

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

August 14 at 4:19 PM | prnewswire.com

A Preview Of Talphera's Earnings

August 13, 2025 | benzinga.com

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

August 7, 2025 | prnewswire.com

Short Interest in Talphera, Inc. (NASDAQ:TLPH) Increases By 107.4%

August 7, 2025 | americanbankingnews.com

talphera receives extension to meet nasdaq listing requirements

June 7, 2025 | investing.com

Talphera Granted Extension for Nasdaq Compliance

June 5, 2025 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 17, 2025 | finanznachrichten.de

Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025

May 16, 2025 | uk.investing.com

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

May 15, 2025 | msn.com

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | prnewswire.com

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS, TLPH, KZIA, and ADIL Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$0.39 0.00 (-0.13%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.39 -0.01 (-2.03%)

As of 08/15/2025 07:37 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Ayala Pharmaceuticals NASDAQ:ADXS

$0.05 0.00 (0.00%)

As of 08/15/2025

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Novogen NASDAQ:KZIA

$8.03 -0.24 (-2.90%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.04 +0.01 (+0.12%)

As of 08/15/2025 04:10 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Talphera NASDAQ:TLPH

$0.43 0.00 (-1.00%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$0.42 -0.01 (-1.48%)

As of 08/15/2025 06:53 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time